Abstract: An endovascular graft including a stent graft and a surgical graft is provided. The stent graft can include an elongated body having a collapsed and expanded configuration and include a frame structure covered by a compression sleeve that retains the elongated body in the collapsed configuration until deployment of the stent graft. The endovascular graft can include a first cuff member sized and dimensioned to extend into a lumen of an aortic arch branch vessel when the endovascular graft is implanted in a subject. The frame structure can include a backstop sized and dimensioned to extend into the first cuff member when the endovascular graft is implanted in the subject. The surgical graft can be partially attached to the stent graft at a proximal end portion thereof.

Abstract: A stent graft (2) for placement in the thoracic arch of a patient has a first tubular body portion (6) with a first lumen therein for placement in the ascending aorta of a patient and a second tubular body portion (8) to extend along the thoracic arch and down the descending aorta. The second tubular body portion is of a lesser diameter than the first tubular body portion. There is a step portion (10) between the first body portion and the second body portion. The step portion is joined to and continuous with the first portion and the second portion. A first side of each of the first body portion, the step portion and the second body portion are substantially aligned so that there is a step (18) defined on a second side opposite to the first side of the body portion. There is an aperture (30) in the step portion and an internal tube (32) extending from the aperture towards the first body portion.

Abstract: Embodiments access a digitized image of tissue demonstrating non-small cell lung cancer (NSCLC), the tissue including a plurality of cellular nuclei; segment the plurality of cellular nuclei represented in the digitized image; extract a set of nuclear radiomic features from the plurality of segmented cellular nuclei; generate at least one nuclear cell graph (CG) based on the plurality of segmented nuclei; compute a set of CG features based on the nuclear CG; provide the set of nuclear radiomic features and the set of CG features to a machine learning classifier; receive, from the machine learning classifier, a probability that the tissue will respond to immunotherapy, based, at least in part, on the set of nuclear radiomic features and the set of CG features; generate a classification of the tissue as a responder or non-responder based on the probability; and display the classification.

Abstract: A ventricular assist device includes a housing including a pumping chamber. A stator assembly is supported in the housing. The stator assembly includes a core having a length measured along a pump axis. A rotating assembly is rotatable relative to the stator assembly about the pump axis. The rotating assembly includes an impeller positioned in the pumping chamber and a rotor magnet. The rotating assembly is movable axially along the pump axis relative to the pump housing and the stator assembly. The rotating assembly includes a rotor magnet configured and arranged such that the magnetic attraction of the rotor magnet to the core urges the rotating assembly to move axially relative to the stator assembly such that a flow regulating portion of the rotating assembly engages with a corresponding portion of the housing to block flow through the pumping chamber when the pump is at rest.

Abstract: Provided herein are compositions, systems, kits, and methods for detecting rejection, or an elevated risk of rejection, of an organ or tissue graft (e.g., kidney graft) in a subject by detecting one, or a panel of, RNA markers in a urine sample from the subject. In certain embodiments, kidney graft injury is detected by measuring one or more of the RNA markers disclosed herein. In some embodiments, the one or more markers are employed to distinguish between acute graft rejection and BK virus nephropathy.

Abstract: A method of providing a prognosis or diagnosis of prostate cancer in a subject is described. The method includes obtaining a urine or prostate sample from the subject; determining the level of expression of ABCA1 in the sample; and comparing the level of expression of ABCA1 in the sample to the level of a control sample, wherein a decreased level of ABCA1 expression compared to the control indicates the subject has prostate cancer or a more severe form of prostate cancer. Methods of treating subjects identified as having prostate cancer, and kits for carrying out the method of prognosis or diagnosis are also described.

Abstract: A system for on-demand delivery of a sterile fluid includes a housing. At least one fluid reservoir is associated with the housing and configured to hold a fluid. A sterilization and/or purification mechanism is in fluid communication with the at least one fluid reservoir. The sterilization and/or purification mechanism is configured to sterilize the fluid. A dispensing mechanism is in fluid communication with the sterilization mechanism and configured to dispense the sterile fluid. A controller is associated with one or more of the housing, the at least one fluid reservoir, the sterilization and/or purification mechanism, and the dispensing mechanism. The controller being configured to modulate at least one operating characteristic of the system. The system is configured to deliver the sterile and/or purified fluid immediately after a request is made.

Abstract: A modular dilation device (100) is provided for inserting multiple dilators into a target patient tissue site. The modular dilation device includes a first dilator (104) and a second dilator (530). The first dilator has a first dilator distal end (108) and a first dilator inner lumen (114). The first dilator has a first dilator side wall opening (118). The first dilator distal end has a first dilator open tip (116). The first dilator has a first dilator open slit (120). The first dilator open slit extends between the first dilator side wall opening and the first dilator open tip. The second dilator has a second dilator distal end and a second dilator inner lumen. The second dilator distal end has a second dilator open tip. When the second dilator is joined to the first dilator, the second dilator open tip is adjacent to the first dilator side wall opening.

Abstract: A biocompatible tissue graft includes a first layer of a bioremodelable collageneous material, a second layer of biocompatible synthetic or natural remodelable or substantially remodelable material attached to the first layer; and at least one fiber that is stitched in a reinforcing pattern in the first layer and/or second layer to mitigate tearing and/or improve fixation retention of the graft, and substantially maintain the improved properties while one or more of the layers is remodeling.

Abstract: Embodiments facilitate predicting a patient prostate cancer (PCa) DECIPHER risk group. A first set of embodiments relates to training of a machine learning classifier to compute a probability that a patient is a member of a DECIPHER low/intermediate risk group based on radiomic features extracted from bi-parametric magnetic resonance imaging (bpMRI) images. A second set of embodiments relates to classifying a patient as a member of DECIPHER low/intermediate risk group, or DECIPHER high-risk group, based on radiomic features extracted from bpMRI imagery of the patient.

Abstract: Provided herein are compositions, systems, kits, and methods for treating cancer in at least one bone of a subject using nanoparticles encapsulating, or conjugated to, an anti-cancer agent. In other embodiments, provided herein are composition, systems, kits, and methods for treating a bone disease (e.g., osteoporosis) in a subject using nanoparticle encapsulating, or conjugated to, a RANKL inhibitor. The nanoparticle are, in certain embodiments, neutral or nearly neutral in charge (e.g., zeta potential between ?5 and +5 mV) and less than 250 nm in diameter on average (e.g. have an average diameter between 100 and 200 nm).

Abstract: A temperature-regulating garment is provided for assisting a user with regulating body temperature. A garment body has first and second major garment body edges. The garment body has a neckline formed by a least a portion of the first major garment body edge. The garment body has a front right panel, a front left panel, and a back panel. At least one armhole is located laterally between the back panel and a selected one of the right front panel and the left front panel. First and second neck pockets are each configured to accept a temperature-regulating pack. The first neck pocket is disposed upon at least one of the right front panel and the back panel, spanning the first major garment body edge. The second neck pocket is disposed upon at least one of the left front panel and the back panel, spanning the first major garment body edge.

Abstract: A method of promoting hair growth of a subject includes administering to follicle cells of the subject a therapeutically effective amount of a TLR2 agonist that promotes TLR2 activation and hair growth of the subject.

Abstract: A computer-implemented method for determining the volume of activation of neural tissue. In one embodiment, the method uses one or more parametric equations that define a volume of activation, wherein the parameters for the one or more parametric equations are given as a function of an input vector that includes stimulation parameters. After receiving input data that includes values for the stimulation parameters and defining the input vector using the input data, the input vector is applied to the function to obtain the parameters for the one or more parametric equations. The parametric equation is solved to obtain a calculated volume of activation.

Abstract: The present invention provides markers and methods for determining whether a subject, particularly a human subject, has or is at risk of developing, a disease such as cardiovascular disease, diabetes mellitus, insulin resistance, metabolic syndrome, NAFLD (Nonalcoholic Fatty Liver Disease) or NASH (Nonalcoholic Steatohepatitis) (e.g., within the ensuing year, two years, and/or three years). The present application also relates to the use of such markers and methods for monitoring the status of such diseases in a subject or the effects of therapeutic agents on subjects with such diseases.

Abstract: A method of preoperative planning comprises creating a virtual model of a native patient tissue; placing a virtual device into a desired device orientation relative to the virtual model of the native patient tissue; specifying at least one structural change to the native patient tissue to facilitate placement of the virtual device in the desired device orientation; creating a virtual model of an altered patient tissue responsive to the specifying at least one structural change to the native patient tissue; and fabricating a tangible representation of a bone using the virtual model of the altered patient tissue.

Abstract: Embodiments facilitate prediction of anti-vascular endothelial growth (anti-VEGF) therapy response in DME or RVO patients. A first set of embodiments discussed herein relates to training of a machine learning classifier to determine a prediction for response to anti-VEGF therapy based on a vascular network organization via Hough transform (VaNgOGH) descriptor generated based on FA images of tissue demonstrating DME or RVO. A second set of embodiments discussed herein relates to determination of a prediction of response to anti-VEGF therapy for a DME or RVO patient (e.g., non-rebounder vs. rebounder, response vs. non-response) based on a VaNgOGH descriptor generated based on FA imagery of the patient.

Abstract: Systems and methods are provided for evaluating a lung via ultrasound. A plurality of ultrasound images are generated at each of a plurality of locations on a lung using an ultrasound imager to provide a plurality of images. Respective grades are assigned to each of the plurality of images according to an amount of B-line artifact in the image to generate a plurality of grades for the lung. A composite score for the lung is calculated from the plurality of grades. The composite score represents a general assessment of the lung. The composite score is provided to a user at an associated output device.

Abstract: Embodiments predict early stage NSCLC recurrence, and include an image acquisition circuit configured to access an image of a region of tissue demonstrating early-stage NSCLC including a plurality of cellular nuclei; a nuclei detecting and segmentation circuit configured to detect a member of the plurality; and classify the member as a tumor infiltrating lymphocyte (TIL) nucleus or non-TIL nucleus; a spatial TIL feature circuit configured to extract spatial TIL features from the plurality, the spatial TIL features including a first subset of features based on the spatial arrangement of TIL nuclei, and a second subset of features based on the spatial relationship between TIL nuclei and non-TIL nuclei; and an NSCLC recurrence classification circuit configured to compute a probability that region will experience recurrence based on the spatial TIL features; and generate a classification of the region as likely or unlikely to experience recurrence based on the probability.

Abstract: A method of recovering progenitor cells from bone marrow aspirate. A bone void filler preparation container is provided. The bone void filler preparation container has an inlet port and an outlet port. A bone graft matrix having a particle size of between about 1,000 ?m and about 2,000 ?m is placed in the bone void filler preparation container. A bone marrow aspirate is passed through the bone void filler preparation container. Progenitor cells in the bone marrow aspirate are retained in the bone void filler preparation container. Greater than about 83 percent of the progenitor cells in the bone marrow aspirate are retained in the bone void filler preparation container.